Company intelligence
Seventure Partners
We actively fund innovative companies within the two evolving fields of Digital technologies and Life sciences.
About Seventure Partners
Seventure Partners is a long term equity investor that actively supports innovative companies aiming at generating positive impacts on Humankind, Society, Sustainability and the Planet. With €950m net commitments under management as of the end of 2022, Seventure is a leading venture capital firm in Europe investing since 1997 in innovative businesses with high growth potential in 2 main areas: Life sciences (Biotech, Health & digital Health, Nutrition, Foodtech, Blue Economy, Aquaculture, Animal & Agriculture, Sport & Wellness …) with a specific interest for microbiome-related innovations across Europe, Israel, Asia and North America and Digital technologies (FinTech, RetailTech etc…) in Western Europe. Investments can range between €500k and €10m per round and up to €20m per company, from early to late stage, growth, pre-IPO and IPO. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank. For more details: www.seventure.com
Verified activity
Signals from Seventure Partners
4 published signals
Capital & Finance
Seventure Partners notes that Samsung Biologics launched a CHF 1.46B all-cash tender offer for PolyPeptide Group, a 40% premium to the last undisturbed price.
Reported by Philippe Tramoy
Capital & Finance
Seventure Partners notes that CordenPharma has committed over 1B€ across three years.
Reported by Philippe Tramoy
Capital & Finance
Seventure Partners notes that Bachem signed a strategic supply deal backing a CHF 500M+ greenfield facility in Sisslerfeld, with production starting only in 2030.
Reported by Philippe Tramoy
Research & Knowledge
Seventure Partners pulled trial data from the EU's CTIS and the global ClinicalTrials.gov database to show that three quarters of cell and gene therapy trials in the EU are still in Phase I or II.
Reported by Philippe Tramoy